Reprogram Biosciences Secures $6M Seed Funding

Deal Summary

Reprogram Biosciences, a preclinical oncology biotech developing mRNA therapeutics for solid tumors, announced the close of its seed financing round, raising $6 million. The round was backed by Unshackled Ventures, 1517 Fund and Narya, bringing total capital raised since its 2025 founding to $6 million.